Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry
Big banks cut thousands of jobs, more layoffs coming
From College Advising to Teacher Preparation: Affirmative Action Ruling May Reshape K-12